# Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

> **NCT00056459** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 1168 (actual)

## Conditions studied

- Colorectal Neoplasms
- Colonic Neoplasms
- Rectal Neoplasms

## Interventions

- **DRUG:** Vatalanib

## Key facts

- **NCT ID:** NCT00056459
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2007-01
- **Final completion:** —
- **Target enrollment:** 1168 (ACTUAL)
- **Last updated:** 2020-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00056459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00056459, "Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00056459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*